Term ends Jun 12, 2033 · Medium confidence
20-year base term ends Jun 12, 2033
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,364,473), so the cap could be lower.
Jun 12, 2013
Jun 12, 2033
Nov 15, 2016
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 12, 2013, when application PCT/US2013/045495, the earliest non-provisional in its chain, was filed (this one was filed Sep 11, 2015) | Jun 12, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,339,497, US 9,364,473, US 9,452,162) | resolves to Jun 12, 2033, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 12, 2033 | Medium confidence |
This family
| Application PCT/US2013/045495 | PCT application no patent term | no patent term |
| US 9,452,162 | In force Jun 2033 | Jun 2033 |
| US 9,339,497 | In force Jun 2033 | Jun 2033 |
| US 9,364,473 | In force no later than Jun 2033 | no later than Jun 2033 |
| US 9,492,442 | this patent Jun 2033 | Jun 2033 |
| Application 15/059,640 | Abandoned not computed | not computed |
| US 9,717,724 | In force Jun 2033 | Jun 2033 |
| Application 15/341,619 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 23, 2015 Reel 37117, frame 262 | Bayever, Eliel; Dhindsa, Navreet; Fitzgerald, Jonathan Basil; Laivins, Peter; Moyo, Victor; Niyikiza, Clet | Merrimack Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Dec 28, 2015 Reel 37394, frame 285 | Merrimack Pharmaceuticals, Inc. | U.S. Bank National Association, as Collateral Agent | Security Interest |
| May 3, 2016 Reel 38598, frame 415 | Kim, Jaeyeon | Merrimack Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Apr 14, 2017 Reel 42254, frame 349 | U.S. Bank National Association | Merrimack Pharmaceuticals, Inc. | Release of Security Interest |
| May 1, 2017 Reel 42377, frame 696 | Merrimack Pharmaceuticals, Inc. | Ipsen Biopharm Ltd. | Assignment of Assignor's Interest |
| May 17, 2017 Reel 42522, frame 334 | Merrimack Pharmaceuticals, Inc. | Ipsen Biopharm Ltd. | Change of Address of Assignee |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 9,339,497, US 9,364,473, US 9,452,162, ends no earlier than this term, so it caps nothing.